Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

356.56 +14.84 (+4.34%)
Streaming Delayed Price Updated: 3:46 PM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 135,635
Open 343.81
Bid (Size) 356.01 (80)
Ask (Size) 356.75 (40)
Prev. Close 341.72
Today's Range 343.81 - 356.98
52wk Range 136.73 - 382.54
Shares Outstanding 22,205,642
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Krystal Biotech (NASDAQ:KRYS) Clears Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
News headline image
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗
The drugmaker should significantly mitigate its most important risk as it develops new products. 
Via The Motley Fool

Performance

YTD
+44.4%
+44.4%
1 Month
+1.3%
+1.3%
3 Month
+17.8%
+17.8%
6 Month
+29.9%
+29.9%
1 Year
+142.9%
+142.9%

More News

Read More
News headline image
Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today ↗
Via Benzinga
Krystal Biotech (NASDAQ:KRYS) Slips After Q2 Revenue Miss Despite EPS Beat ↗
Via Chartmill
Krystal Biotech (NASDAQ:KRYS) Shows High-Growth Momentum With Perfect Minervini Trend Template Setup ↗
Via Chartmill
Krystal Biotech (NASDAQ:KRYS) Combines Perfect Trend Template with High-Growth Momentum ↗
Via Chartmill
News headline image
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
From Biotech Insider
Via GlobeNewswire
News headline image
Krystal Biotech Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Krystal Biotech (NASDAQ:KRYS) Surges After Q1 Beat as VYJUVEK Revenue Hits $116.4M ↗
Via Chartmill
News headline image
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead ↗
Via The Motley Fool
Topics Economy
News headline image
Why Tutor Perini Stock Trounced the Market on Tuesday ↗
Via The Motley Fool
Topics Stocks
News headline image
3 Soaring Stocks That May Have More Upside Ahead ↗
Via The Motley Fool
News headline image
3 Biotech Firms With Major Potential Catalysts in the Coming Months ↗
Via MarketBeat
Topics Intellectual Property
News headline image
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead ↗
Via The Motley Fool
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Tech Fund Made a $5.8 Million Bet on an AI Chip Stock Up Nearly 200% Post-IPO ↗
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering Regulatory Compliance
News headline image
This AI Semiconductor Stock Beat the S&P 500 by 9 Points. A Fund Just Exited Completely ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance Stocks
News headline image
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗
Via The Motley Fool
News headline image
Krystal (KRYS) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Krystal (KRYS) Q1 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Is Paymentus Stock a Buy After Palisades Investment Partners Increased Its Stake By $6 Million? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Amprius Technologies Stock a Buy After Palisades Investment Partners Initiated a Position Worth $4.8 Million? ↗
Via The Motley Fool
Topics Electric Vehicles Regulatory Compliance
News headline image
Palisades Investment Partners Initiated a Position in SkyWater Technology Stock. What Does This Mean for Investors? ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Krystal Biotech, Inc. - Common Stock publicly traded?
Yes, Krystal Biotech, Inc. - Common Stock is publicly traded.
What exchange does Krystal Biotech, Inc. - Common Stock trade on?
Krystal Biotech, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Krystal Biotech, Inc. - Common Stock?
The ticker symbol for Krystal Biotech, Inc. - Common Stock is KRYS on the Nasdaq Stock Market
What is the current price of Krystal Biotech, Inc. - Common Stock?
The current price of Krystal Biotech, Inc. - Common Stock is 356.56
When was Krystal Biotech, Inc. - Common Stock last traded?
The last trade of Krystal Biotech, Inc. - Common Stock was at 08/25/26 03:46 PM ET
What is the market capitalization of Krystal Biotech, Inc. - Common Stock?
The market capitalization of Krystal Biotech, Inc. - Common Stock is 7.92B
How many shares of Krystal Biotech, Inc. - Common Stock are outstanding?
Krystal Biotech, Inc. - Common Stock has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.